Australia Legal Cannabis Market By Source (Hemp, Marijuana), By Derivatives (CBD, THC, Others), By Cultivation (Indoor Cultivation, Greenhouse Cultivation, Outdoor Cultivation), By End Use (Industrial Use, Medical Use, Recreational Use), By Region and Competition, Forecast & Opportunities, 2020-2030F
Market Overview
The Australia Legal Cannabis Market reached a valuation of USD 126.32 million in 2024 and is projected texpand tUSD 420.33 million by 2030, reflecting a robust CAGR of 22.16%. This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector. The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is alsgaining traction as companies invest in localized cultivation and processing infrastructure, aiming tenhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues tboost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings—such as oils, capsules, and topicals—and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export.
Key Market Drivers
Favorable Regulatory Environment and Policy Support
A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access tcannabis treatments when conventional methods fall short. Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though nproducts have yet gained OTC approval, this shift highlights the government's intent tbroaden access tnon-psychoactive cannabis applications. These changes not only enhance patient reach but alsencourage foreign investment, support pharmaceutical innovation, and elevate Australia’s standing as a regulated and export-ready cannabis market.
Key Market Challenges
High Costs of Production and Patient Access
The Australia Legal Cannabis Market faces significant hurdles due tthe high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients—particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS). As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds taccess difficulties. Together, these financial and procedural barriers hinder the market’s growth potential and restrict the widespread adoption of cannabis-based treatments.
Key Market Trends
Surge in Demand for Low-Dose CBD and OTC Access
A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up t150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription. While nsuch products have yet received approval, the regulatory shift signals expanded access tcannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies tinvest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming tsecure a share in this emerging OTC segment.
Key Market Players
In this report, the Australia Legal Cannabis Market has been segmented intthe following categories, in addition tthe industry trends which have alsbeen detailed below:
Company Profiles: Detailed analysis of the major companies present in the Australia Legal Cannabis Market.
Available Customizations:
Australia Legal Cannabis Market report with the given market data, TechSci Research offers customizations according ta company's specific needs. The following customization options are available for the report:
Company Information
The Australia Legal Cannabis Market reached a valuation of USD 126.32 million in 2024 and is projected texpand tUSD 420.33 million by 2030, reflecting a robust CAGR of 22.16%. This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector. The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is alsgaining traction as companies invest in localized cultivation and processing infrastructure, aiming tenhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues tboost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings—such as oils, capsules, and topicals—and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export.
Key Market Drivers
Favorable Regulatory Environment and Policy Support
A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access tcannabis treatments when conventional methods fall short. Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though nproducts have yet gained OTC approval, this shift highlights the government's intent tbroaden access tnon-psychoactive cannabis applications. These changes not only enhance patient reach but alsencourage foreign investment, support pharmaceutical innovation, and elevate Australia’s standing as a regulated and export-ready cannabis market.
Key Market Challenges
High Costs of Production and Patient Access
The Australia Legal Cannabis Market faces significant hurdles due tthe high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients—particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS). As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds taccess difficulties. Together, these financial and procedural barriers hinder the market’s growth potential and restrict the widespread adoption of cannabis-based treatments.
Key Market Trends
Surge in Demand for Low-Dose CBD and OTC Access
A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up t150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription. While nsuch products have yet received approval, the regulatory shift signals expanded access tcannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies tinvest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming tsecure a share in this emerging OTC segment.
Key Market Players
- Cann Group Limited
- Zelira Therapeutics
- AusCann Group Holdings Ltd.
- Bod Australia
- Althea Group
- ECOFIBRE
- Botanix Pharmaceuticals
- EPSILON
- Little Green Pharma
- Incannex
In this report, the Australia Legal Cannabis Market has been segmented intthe following categories, in addition tthe industry trends which have alsbeen detailed below:
- Australia Legal Cannabis Market, By Source:
- Hemp
- Marijuana
- Australia Legal Cannabis Market, By Derivatives:
- CBD
- THC
- Others
- Australia Legal Cannabis Market, By Cultivation:
- Indoor Cultivation
- Greenhouse Cultivation
- Outdoor Cultivation
- Australia Legal Cannabis Market, By End Use:
- Industrial Use
- Medical Use
- Recreational Use
- Australia Legal Cannabis Market, By Region:
- Victoria & Tasmania
- Queensland
- Western Australia
- Northern Territory & Southern Australia
- Australia Capital Territory & New South Wales
Company Profiles: Detailed analysis of the major companies present in the Australia Legal Cannabis Market.
Available Customizations:
Australia Legal Cannabis Market report with the given market data, TechSci Research offers customizations according ta company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up tfive).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Source (Hemp, Marijuana)
5.2.2. By Derivatives (CBD, THC, Others)
5.2.3. By Cultivation (Indoor Cultivation, Greenhouse Cultivation, Outdoor Cultivation)
5.2.4. By End Use (Industrial Use, Medical Use, Recreational Use)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. VICTORIA & TASMANIA AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Source
6.2.2. By Derivatives
6.2.3. By Cultivation
6.2.4. By End Use
7. QUEENSLAND LEGAL CANNABIS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Source
7.2.2. By Derivatives
7.2.3. By Cultivation
7.2.4. By End Use
8. WESTERN AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Source
8.2.2. By Derivatives
8.2.3. By Cultivation
8.2.4. By End Use
9. NORTHERN TERRITORY & SOUTHERN AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Source
9.2.2. By Derivatives
9.2.3. By Cultivation
9.2.4. By End Use
10. AUSTRALIA CAPITAL TERRITORY & NEW SOUTH WALES LEGAL CANNABIS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Source
10.2.2. By Derivatives
10.2.3. By Cultivation
10.2.4. By End Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. POLICY & REGULATORY LANDSCAPE
14. AUSTRALIA ECONOMIC PROFILE
15. AUSTRALIA LEGAL CANNABIS MARKET: SWOT ANALYSIS
16. PORTER’S FIVE FORCES ANALYSIS
16.1. Competition in the Industry
16.2. Potential of New Entrants
16.3. Power of Suppliers
16.4. Power of Customers
16.5. Threat of Substitute Products
17. COMPETITIVE LANDSCAPE
17.1. Cann Group Limited
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. Zelira Therapeutics
17.3. AusCann Group Holdings Ltd.
17.4. Bod Australia
17.5. Althea Group
17.6. ECOFIBRE
17.7. Botanix Pharmaceuticals
17.8. EPSILON
17.9. Little Green Pharma
17.10. Incannex
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Source (Hemp, Marijuana)
5.2.2. By Derivatives (CBD, THC, Others)
5.2.3. By Cultivation (Indoor Cultivation, Greenhouse Cultivation, Outdoor Cultivation)
5.2.4. By End Use (Industrial Use, Medical Use, Recreational Use)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. VICTORIA & TASMANIA AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Source
6.2.2. By Derivatives
6.2.3. By Cultivation
6.2.4. By End Use
7. QUEENSLAND LEGAL CANNABIS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Source
7.2.2. By Derivatives
7.2.3. By Cultivation
7.2.4. By End Use
8. WESTERN AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Source
8.2.2. By Derivatives
8.2.3. By Cultivation
8.2.4. By End Use
9. NORTHERN TERRITORY & SOUTHERN AUSTRALIA LEGAL CANNABIS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Source
9.2.2. By Derivatives
9.2.3. By Cultivation
9.2.4. By End Use
10. AUSTRALIA CAPITAL TERRITORY & NEW SOUTH WALES LEGAL CANNABIS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Source
10.2.2. By Derivatives
10.2.3. By Cultivation
10.2.4. By End Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. POLICY & REGULATORY LANDSCAPE
14. AUSTRALIA ECONOMIC PROFILE
15. AUSTRALIA LEGAL CANNABIS MARKET: SWOT ANALYSIS
16. PORTER’S FIVE FORCES ANALYSIS
16.1. Competition in the Industry
16.2. Potential of New Entrants
16.3. Power of Suppliers
16.4. Power of Customers
16.5. Threat of Substitute Products
17. COMPETITIVE LANDSCAPE
17.1. Cann Group Limited
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. Zelira Therapeutics
17.3. AusCann Group Holdings Ltd.
17.4. Bod Australia
17.5. Althea Group
17.6. ECOFIBRE
17.7. Botanix Pharmaceuticals
17.8. EPSILON
17.9. Little Green Pharma
17.10. Incannex
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
